AN Venture Partners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/AN Venture Partners/Activity

AN Venture Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Led Typewriter Therapeutics' $56M Series A as the company emerged from stealth with an RNA-based, non-viral in vivo gene insertion platform.

Typewriter Therapeutics

Typewriter Therapeutics AN Venture Partners

prnewswire.comSEP 2, 2026

SEP 2, 2026

Investment

Participated as an existing investor in Crystalys Therapeutics' oversubscribed $130M Series B, led by Frazier Life Sciences, to advance dotinurad through Phase 3 trials for gout.

Crystalys Therapeutics

Crystalys Therapeutics AN Venture Partners

medcitynews.comJUL 2026

JUL 2026

Milestone

Portfolio company City Therapeutics closed a $99.5M Series B to advance its next-generation RNAi therapeutics pipeline.

City Therapeutics

City Therapeutics AN Venture Partners

biospace.comJUN 8, 2026

JUN 8, 2026

Investment

Led Tortugas Neuroscience' launch with $106M to advance a clinical-stage pipeline targeting neurology and neuropsychiatric disorders.

Tortugas Neuroscience

Tortugas Neuroscience AN Venture Partners

businesswire.comAPR 21, 2026

APR 21, 2026

Milestone

Portfolio company Imbria Pharmaceuticals announced an extension of its Series B financing to advance ninerafaxstat for cardiovascular disease.

Imbria Pharmaceuticals

Imbria Pharmaceuticals AN Venture Partners

globenewswire.comNOV 17, 2025

NOV 17, 2025

Milestone

Portfolio company Crystalys Therapeutics dosed the first patients in global Phase 3 trials of dotinurad for gout.

Crystalys Therapeutics

Crystalys Therapeutics AN Venture Partners

clinicaltrialsarena.comOCT 22, 2025

OCT 22, 2025

New Fund

Closed ANV Fund I at $200M, one of the largest Japan-focused biotech VC funds to date, backed by 20+ LPs including Japan Investment Corporation and Shionogi.

ANV Fund I

AN Venture Partners

fiercebiotech.comJUN 2025

JUN 2025

Milestone

Portfolio company City Therapeutics announced a strategic research collaboration with Biogen to develop novel RNAi-based therapies.

City Therapeutics

City Therapeutics AN Venture Partners

citytx.comMAY 27, 2025

MAY 27, 2025